Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.71 |
| ▸ | GAK | O14976 | 1/20 | 0.67 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.67 |
| ▸ | BUB1 | O43683 | 1/20 | 0.67 |
| ▸ | STK10 | O94804 | 1/20 | 0.67 |
| ▸ | CARS1 | P49589 | 1/20 | 0.67 |
| ▸ | MAP3K1 | Q13233 | 1/20 | 0.67 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.67 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.67 |
| ▸ | ABL1 | P00519 | 4/20 | 0.64 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.64 |
| ▸ | SRC | P12931 | 4/20 | 0.64 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19314794 | 0.85 | EGFR (0.76) | EGFRGAKRIPK2BUB1STK10 | |
| SCHEMBL21967048 | 0.84 | EGFR (0.76) | EGFRGAKRIPK2BUB1STK10 | |
| SCHEMBL5843315 | 0.83 | EGFR (1.00) | EGFRGAKRIPK2BUB1STK10 | |
| SCHEMBL5842785 | 0.83 | EGFR (1.00) | EGFRGAKRIPK2BUB1STK10 | |
| SCHEMBL5842496 | 0.83 | EGFR (1.00) | EGFRGAKRIPK2BUB1STK10 | |
| SCHEMBL5843277 | 0.83 | EGFR (1.00) | EGFRGAKRIPK2BUB1STK10 | |
| SCHEMBL15339251 | 0.82 | EGFR (0.79) | EGFRGAKRIPK2BUB1STK10 | |
| SCHEMBL2102234 | 0.82 | EGFR (0.74) | EGFRGAKRIPK2BUB1STK10 | |
| SCHEMBL18700228 | 0.81 | EGFR (0.69) | EGFRGAKRIPK2BUB1STK10 | |
| Icotinib SCHEMBL29355667 | 0.80 | EGFR (1.00) | EGFRGAKRIPK2BUB1STK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190321369-A1 | ICOTINIB-CONTAINING TOPICAL SKIN PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2019-10-24 | — | — | US | disclosed |
| EP-3008071-B1 | POLYMORPHIC FORM OF ICOTINIB AND USES THEREOF | BETTA PHARMACEUTICALS CO LTD (CN) | 2018-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190321369-A1 | ICOTINIB-CONTAINING TOPICAL SKIN PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | TYR, ABL1, LCK | EGFR 83/4885GAK 301/4885RIPK2 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.